Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading ->
Disclosure of costs for drug research and development (R&D) and “alternative financing mechanisms” for new health products remain outstanding points to be resolved by countries in finalising a draft United Nations General Assembly political declaration on universal health coverage (UHC). A final draft of the declaration had been expected this week, but as of Friday […] Continue reading ->
Japan said on Friday that it disagrees with aspects of an already-adopted Human Rights Council (HRC) resolution on access to medicines, claiming that there is no evidence that “delinkage” between the cost of research & development (R&D) and the price of medicines improves access to medicines. Japan also disagreed with pursuing alternative frameworks for R&D […] Continue reading ->
If the fight against cancer has yielded substantial results on survival rates in high-income countries, low- and middle-income countries are lagging behind, while cancer is gaining ground, with a particularly worrying trend in children. A first-ever International Health Congress on Integrative Oncology, held 28-30 June in Geneva, presented traditional and alternative medicines as precious allies […] Continue reading ->
A new plan to improve collaboration across 12 United Nations and multilateral agencies to support UN member states to reach 2030 targets on health includes not only the ambitious aim of reducing bureaucracy and increasing efficiency, but of working better across sectors to address environmental, commercial and social factors that harm health. These factors, which […] Continue reading ->
WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading ->